Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

PL Tharaux, G Pialoux, A Pavot, X Mariette… - The Lancet …, 2021 - thelancet.com
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
被引用次数：257 相关文章

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

PL Tharaux, G Pialoux, A Pavot, X Mariette… - The Lancet Respiratory …, 2021 - Elsevier
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.

The Lancet. Respiratory Medicine, 2021 - europepmc.org
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

[引用][C] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

PL Tharaux, G Pialoux, A Pavot, X Mariette… - The Lancet Respiratory …, 2021 - cir.nii.ac.jp
[HTML] hal.science

[HTML][HTML] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

PL Tharaux, G Pialoux, A Pavot, X Mariette… - The Lancet Respiratory …, 2021 - hal.science
Background: Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …
[HTML] nih.gov

[HTML][HTML] Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

CORIMUNO-19 Collaborative group - The Lancet. Respiratory …, 2021 - ncbi.nlm.nih.gov
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

CORIMUNO-19 Collaborative group - 2021 - pubmed.ncbi.nlm.nih.gov
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine… - 2021 - agris.fao.org
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate
pneumonia (CORIMUNO-ANA-1): a randomised controlled trial Food and Agriculture …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.

The Lancet. Respiratory Medicine, 2021 - europepmc.org
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

CORIMUNO-19 Collaborative group - 2021 - pubmed.ncbi.nlm.nih.gov
Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …